Polymer Capital Management HK LTD Takes $1.24 Million Position in DBV Technologies S.A. $DBVT

Polymer Capital Management HK LTD acquired a new stake in DBV Technologies S.A. (NASDAQ:DBVT) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 64,500 shares of the company’s stock, valued at approximately $1,236,000. Polymer Capital Management HK LTD owned 0.16% of DBV Technologies at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in DBVT. Allworth Financial LP bought a new stake in DBV Technologies in the fourth quarter valued at approximately $32,000. New York State Common Retirement Fund bought a new position in shares of DBV Technologies in the 3rd quarter worth $34,000. GAMMA Investing LLC lifted its holdings in shares of DBV Technologies by 38.4% in the 4th quarter. GAMMA Investing LLC now owns 2,680 shares of the company’s stock worth $51,000 after purchasing an additional 744 shares in the last quarter. Two Sigma Investments LP bought a new position in shares of DBV Technologies in the 3rd quarter worth $167,000. Finally, Citadel Advisors LLC bought a new position in shares of DBV Technologies in the 3rd quarter worth $220,000. 71.74% of the stock is currently owned by institutional investors.

DBV Technologies Price Performance

NASDAQ:DBVT opened at $17.42 on Friday. The business has a 50 day moving average of $19.42 and a 200 day moving average of $19.64. The company has a market capitalization of $1.03 billion, a price-to-earnings ratio of -3.91 and a beta of -0.99. DBV Technologies S.A. has a 1-year low of $8.50 and a 1-year high of $26.18.

DBV Technologies (NASDAQ:DBVT) last released its earnings results on Thursday, April 30th. The company reported ($0.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.42). DBV Technologies had a negative return on equity of 129.88% and a negative net margin of 2,895.37%.The firm had revenue of $0.90 million during the quarter, compared to the consensus estimate of $1.11 million. As a group, sell-side analysts anticipate that DBV Technologies S.A. will post -0.47 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on DBVT. Wall Street Zen upgraded DBV Technologies from a “sell” rating to a “hold” rating in a research note on Saturday, May 2nd. Guggenheim reissued a “buy” rating and issued a $51.00 price objective on shares of DBV Technologies in a report on Monday, May 4th. Citigroup reissued an “outperform” rating on shares of DBV Technologies in a report on Friday, May 1st. Finally, Citizens Jmp lifted their target price on DBV Technologies from $47.00 to $55.00 and gave the company a “market outperform” rating in a report on Friday, May 1st. Two analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $48.50.

About DBV Technologies

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.